PER.AX
Price:
$0.007
Market Cap:
$7.61M
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hor...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2023-12-26
Stock Exchange
ASX
Ticker
PER.AX
According to Percheron Therapeutics Limited’s latest financial reports and current stock price. The company's current PE Ratio is -0.70. This represents a change of -48.25% compared to the average of -1.35 of the last 4 quarters.
The mean historical PE Ratio of Percheron Therapeutics Limited over the last ten years is -4.40. The current -0.70 PE Ratio has changed 1.49% with respect to the historical average. Over the past ten years (40 quarters), PER.AX's PE Ratio was at its highest in in the June 2002 quarter at 0. The PE Ratio was at its lowest in in the June 2024 quarter at -2.51.
Average
-4.40
Median
-4.34
Minimum
-7.74
Maximum
-0.69
Discovering the peaks and valleys of Percheron Therapeutics Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 62.62%
Maximum Annual PE Ratio = -0.69
Minimum Annual Increase = -131.20%
Minimum Annual PE Ratio = -7.74
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -0.69 | -84.72% |
| 2024 | -4.49 | 29.46% |
| 2023 | -3.47 | -46.13% |
| 2022 | -6.44 | 62.62% |
| 2021 | -3.96 | -13.01% |
| 2020 | -4.55 | -41.16% |
| 2019 | -7.74 | 57.04% |
| 2018 | -4.93 | 39.55% |
| 2017 | -3.53 | -15.85% |
| 2016 | -4.19 | -131.20% |
The current PE Ratio of Percheron Therapeutics Limited (PER.AX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.88
5-year avg
-3.81
10-year avg
-4.40
Percheron Therapeutics Limited’s PE Ratio is greater than Invion Limited (-0.84), less than Cann Group Limited (-0.21), less than Intelicare Holdings Limited (0), greater than Bio-Gene Technology Limited (-2.85), greater than Invex Therapeutics Ltd (-18.99), greater than HITIQ Limited (-2.05), greater than ECS Botanics Holdings Ltd (-1.36), less than Adherium Limited (-0.33), greater than Memphasys Limited (-1.61), greater than Vectus Biosystems Limited (-3.30),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.84 | $8.22M | |
| -0.21 | $5.63M | |
| 0 | $10.52M | |
| -2.85 | $7.93M | |
| -18.99 | $9.02M | |
| -2.05 | $12.67M | |
| -1.36 | $7.75M | |
| -0.33 | $7.71M | |
| -1.61 | $9.82M | |
| -3.30 | $5.87M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Percheron Therapeutics Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Percheron Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Percheron Therapeutics Limited's PE Ratio?
How is the PE Ratio calculated for Percheron Therapeutics Limited (PER.AX)?
What is the highest PE Ratio for Percheron Therapeutics Limited (PER.AX)?
What is the 3-year average PE Ratio for Percheron Therapeutics Limited (PER.AX)?
What is the 5-year average PE Ratio for Percheron Therapeutics Limited (PER.AX)?
How does the current PE Ratio for Percheron Therapeutics Limited (PER.AX) compare to its historical average?